Hyperuricemia is a known cardiovascular risk factor. The angiotensin II receptor blocker (ARB) losartan is known to decrease serum uric acid (UA) level. A recent in vitro study demonstrated a strong interaction between irbesartan and UA transporters that exceeded that of losartan. The purpose of the present study was to evaluate the hypouricemic effect of irbesartan in a clinical setting. A total of 40 high-risk hypertensive outpatients with coronary artery disease, cerebrovascular disease and/or diabetes complications who were taking ARBs other than irbesartan and losartan were enrolled in this study. After a 4-week control period, the patients' prescribed ARBs were exchanged for an equivalent dose of irbesartan. We assessed blood pressure, heart rate, serum UA level, parameters of lipid and glucose metabolism, cardiac and renal function and inflammatory and oxidative stress markers in blood samples taken immediately before the initiation of irbesartan treatment and again after 12 weeks of treatment. All 40 recruited patients were followed (31 men and 9 women, mean age: 68 years) without any dropouts. During the 12 weeks of irbesartan treatment, no significant changes in blood pressure, heart rate, parameters of lipid or glucose metabolism or other biomarkers of cardiac function, renal function, or inflammation were observed. However, UA level (5.9 ± 1.6 to 5.5 ± 1.6 mg ml − 1 , P = 0.028) and the oxidative stress marker derivative reactive oxygen metabolites (dROMs) (354 ± 83 to 310 ± 65 U.CARR, Po0.001) were significantly lower at 12 weeks of treatment compared with before treatment. These results suggest that irbesartan has beneficial effects on hyperuricemia and oxidative stress.
INTRODUCTION
Hyperuricemia is recognized as a risk factor for cardiovascular diseases, such as hypertension, 1-4 coronary artery disease and heart failure 5, 6 and type 2 diabetes. 7 Recent data also indicate that serum uric acid (UA) is a risk marker for progression of chronic kidney disease. [8] [9] [10] The angiotensin II receptor blocker (ARB) losartan has been shown to increase urinary UA excretion and, consequently, to decrease serum UA level. 11, 12 However, other ARBs, such as candesartan and valsartan, do not lower serum UA level. 13, 14 A recent in vitro experiment found a strong interaction between irbesartan and UA transporters that exceeded that of losartan. 15 In addition, a clinical report showed that irbesartan tended to decrease serum UA level in hypertensive patients with hyperuricemia. 16 However, very few reports have studied the hypouricemic effect of irbesartan.
We recently reported that irbesartan improved lipid metabolism and oxidative stress in high-risk hypertension patients. 17 The aim of this study was to determine whether irbesartan also lowers serum UA level in high-risk hypertension patients in a routine clinical setting.
METHODS

Study design
We recruited 40 outpatients with high-risk hypertension complicated by coronary artery disease, cerebrovascular disease or diabetes. All patients had been taking ARBs other than irbesartan and losartan for 43 months and had stable blood pressure. We provided an additional 4-week control period to select patients with well-controlled blood pressure, systolic blood pressure o135 mm Hg and diastolic blood pressure o85 mm Hg. After this period, all patients were switched to irbesartan at a dose equivalent to that of their former ARB. We assessed blood pressure and heart rate and collected blood for measurement of serum UA, lipid and glucose metabolism parameters, cardiac and renal function parameters and inflammatory and oxidative stress markers at two time points: immediately before and 12 weeks after initiation of irbesartan treatment. During the 12-week treatment period, irbesartan doses were not changed. At each blood sampling, fasting venous blood was taken from an antecubital vein and was first used for routine blood tests. The remaining blood was immediately centrifuged at 1500 × g for 15 min at room temperature and was then used for measurement of specific biomarkers. The serum was frozen and stored at − 80°C until analysis. The study protocol was approved by the local medical ethics committee, and informed consent was obtained from all patients.
Measurements
Serum UA level was measured by the uricase peroxidase method. The following lipid and glucose metabolism parameters were measured: levels of serum total cholesterol, triglyceride, high-density lipoprotein (HDL) cholesterol, fasting blood glucose and glycohemoglobin (Hb) A1c. Total cholesterol and triglyceride levels were determined using enzymatic methods. HDL cholesterol was measured by the precipitation method. Fasting blood glucose was measured by the glucose oxidase method. HbA1c was measured by high-performance liquid chromatography and was expressed according to the National Glycohemoglobin Standardization Program. Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald formula: LDL cholesterol (mg dl − 1 ) = total cholesterol − HDL cholesterol − (triglycerides/5). For patients with triglyceride levels exceeding 400 mg dl − 1 , LDL cholesterol was not calculated. N-terminal pro-brain natriuretic peptide (NT-proBNP) was measured using a Roche Diagnostic NT-proBNP electrochemiluminescence immunoassay kit and a Elecsys 2010 analyzer (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instructions. 18 Serum creatinine was measured using an enzymatic method, and estimated glomerular filtration rate (eGFR) was calculated using the formula of the Japanese Society of Nephrology CKD Practice Guide: eGFR (ml min − 1 per 1.73 m 2 ) = 194 × (serum creatinine (mg/dl − 1 )) − 1.094 × (age (years)) − 0.287 . For female patients, the product of this equation was multiplied by a correction factor of 0.739. 19 High-sensitivity C-reactive protein (hsCRP) level was measured using particle-enhanced technology on a Behring BN II nephelometer (Dade Behring, Newark, DE, USA) with monoclonal anti-CRP antibodies and a calibrator that was traceable to the World Health Organization Reference Material. 20 Oxidative stress is defined as an imbalance between the production of reactive oxygen metabolites (ROMs) (that is, metabolites of reactive oxygen species) and the removal of reactive oxygen species by a variety of endogenous and exogenous antioxidants. In this study, we assessed oxidative stress via a simple method for the quantification of ROMs, the dROM test, that we had introduced previously. 17 The dROM test is a photometric method based on the radical reaction of Fenton. The test measures hydroperoxides that are strongly correlated with the amount of ROMs and free radicals. [21] [22] [23] 
Data analysis
Values are expressed as the mean ± s.d. Changes in values were assessed by paired t-test. A P-value of o0.05 was considered statistically significant.
RESULTS
All 40 recruited patients completed follow-up (31 men and 9 women, mean age: 68 years). The previously prescribed ARBs included candesartan in 10 subjects (25%), valsartan in 12 subjects (30%), olmesartan in 6 subjects (15%) and telmisartan in 12 subjects (30%). The antihypertensive drugs given in combination with the ARBs were calcium channel blockers in 22 subjects (55%), β-blockers in 5 subjects (13%), α-blockers in 6 subjects (15%) and thiazide diuretics in 4 subjects (10%). Antidiabetic drugs and statins were being taken by 14 (35%) and 35 patients (88%), respectively (Table 1) . None of these drugs were discontinued during the study period. The dose of irbesartan was 50 mg per day in 6 patients (15%), 100 mg per day in 18 patients (45%) and 200 mg per day in 16 patients (40%).
The parameters measured before and after irbesartan treatment are shown in Table 2 . There were no significant changes in systolic (124 ± 12 to 122 ± 12 mm Hg) or diastolic blood pressure (72 ± 7 to 70 ± 6 mm Hg) or heart rate during irbesartan treatment. The levels of total cholesterol, LDL cholesterol, HDL cholesterol, triglyceride, fasting blood glucose, HbA1c, NT-proBNP, eGFR and hsCRP did not change significantly during irbesartan treatment. However, the levels of serum UA (5.9 ± 1.6 to 5.5 ± 1.6 mg ml − 1 , P = 0.028) and dROMs (354 ± 83 vs. 310± 65 U.CARR, Po0.001) decreased significantly during the 12 weeks of treatment ( Table 2 and Figure 1 ). Subanalyses of changes in UA level in patients whose baseline level was greater than the median value of 5.8 mg dl − 1 (Upper Group, n = 20) and in patients whose baseline level was 5.8 mg dl − 1 (Lower Group, n = 20) were performed. The UA level in the Upper Group decreased significantly during irbesartan treatment (from 7.0 ± 0.9 to 6.4 ± 1.4 mg dl − 1 , P = 0.017). However, the UA level in the Lower Group did not change significantly during irbesartan treatment (from 4.6 ± 1.0 to 4.7 ± 0.9 mg dl − 1 , P = 0.641; Figure 2 ).
DISCUSSION
The major findings of our study were reductions in the levels of serum UA and dROMs after irbesartan had been substituted for ARBs other than losartan for 12 weeks. These results suggest that irbesartan is more effective at reducing serum UA and oxidative stress than other ARBs (except losartan).
Several publications have reported the hypouricemic effect of losartan that appears to be mediated by reduction of human urate transporter 1 (URAT1) level, leading to decreased net reabsorption of urate, or UA, in the proximal tubule. [24] [25] [26] The proximal tubule has been identified as the primary location for UA secretion and reabsorption. URAT1 has been shown to have a central role in proximal tubular UA reabsorption. URAT1 is located in the cell membrane on the luminal side of proximal tubular cells, and it reabsorbs UA in exchange for intracellular inorganic anions. Losartan increases UA excretion by inhibiting URAT1-mediated renal tubular UA reabsorption. Early studies in healthy populations showed that the peak uricosuric effects of losartan were observed 2-4 h after administration. The time course of this effect suggests that it is losartan itself rather than its active metabolite that blocks URAT1 and causes the reduction in serum UA level. 27 Recently, Nakamura et al. 15 demonstrated that irbesartan has a similar or stronger hypouricemic effect to that of losartan that is also due to inhibition of URAT1mediated renal tubular UA reabsorption. Therefore, the results of the present study support this previous report.
Theoretically, the uricosuric effects of irbesartan and losartan could increase urinary UA concentration, potentially causing supersaturation of urine with UA and, in extreme cases, UA nephropathy due to precipitation of UA crystals. However, the risk of developing UA crystals with these ARBs is reduced because of their urinary alkalinizing effects. The increase in urinary pH caused by these ARBs is attributed to blockade of angiotensin II-induced stimulation of bicarbonate reabsorption. 28 These findings support the hypothesis that uric acid-lowering therapy slows the progression of chronic kidney disease. Losartan's effect on serum UA level explains 20% of its renoprotective effect. 29 The renoprotective effects of irbesartan in hypertensive patients with diabetic nephropathy have been established in large clinical trials. 30, 31 Based on the results of the present study, we hypothesize that the renoprotective effects of irbesartan may also be partially due to a reduction in serum UA level. We previously found that irbesartan has antioxidant effects, manifested by a reduction of dROMs, in our own I-Mets (irbesartan's metabolic, anti-inflammatory and antioxidant properties) study. 17 Irbesartan was also shown to lower dROMs in the present study. UA is the final product of purine metabolism in humans. The terminal two reactions in its production, that is, the conversion of hypoxanthine to xanthine and the conversion of the latter to UA, are catalyzed by xanthine oxidoreductase that has two interconvertible forms, xanthine dehydrogenase and xanthine oxidase. The latter uses molecular oxygen as an electron acceptor and generates superoxide anions and other reactive oxygen products. 32 The role of UA in conditions associated with oxidative stress is not clear. Evidence, mainly from epidemiologic studies, suggests that increased serum UA level is a risk factor for cardiovascular diseases in which oxidative stress plays an important pathophysiologic role. Allopurinol, a xanthine oxidoreductase inhibitor that lowers serum UA, also exerts protective effects in situations associated with oxidative stress. 32 Recently, experimental and clinical evidence that UA plays an important role in vivo as an antioxidant has been accumulating. One of several hypotheses regarding the role of UA in vivo is that, in contrast to the deleterious effect of hyperuricemia in the etiology of gout and lifestyle-related diseases, UA may be beneficial as a powerful antioxidant. 33, 34 Hence, researchers have suggested that hyperuricemia might be a compensatory response to counteract excessive oxidative stress. 34 In fact, intensive exercise-induced oxidative stress was shown to be reduced by intravenous infusion of UA. 34 Hyperuricemia may be a response to increased oxidative stress associated with obesity. 35 Tsukimori et al. 36 reported that increased serum UA level was closely correlated with plasma hydrogen peroxide level and plasma protein carbonyl level and, thus, served as an indicator of underlying oxidative stress. In the present study, as there was no correlation between the reduction of UA and the reduction of dROMs by irbesartan, the antioxidant effect of irbesartan might be independent of its UA-lowering effect. Chiarelli et al. 37 demonstrated that irbesartan treatment can substantially increase antioxidant enzyme (catalase and glutathione peroxidase) activity and production and, consequently, the levels of oxidative stress markers (serum malondialdehyde, fluorescent products of lipid peroxidation, monocyte chemoattractant protein-1 and 8-isoprostanes prostaglandin F 2α ). These findings provide a potential explanation for the antioxidant effects of irbesartan in the participants of the present study.
Our previous I-Mets study 17 demonstrated that irbesartan also improved lipid metabolism and suppressed inflammation. These effects of irbesartan may be partly attributed to an increase in adiponectin levels. 38 We observed an increase in HDL cholesterol level and a decrease in plasma triglyceride and hsCRP levels associated with a decrease in dROMs. However, in the present study, no significant changes in HDL cholesterol, triglycerides or hsCRP levels Changes of UA in both groups Figure 2 Changes in the UA level in patients whose baseline levels were the median value of ≥ 5.8 mg dl − 1 (Upper Group, n = 20) compared with those in whom they were ˂5.8 mg dl − 1 (Lower Group, n = 20). The UA level in the Upper Group decreased significantly during irbesartan treatment (from 7.0 ± 0.9 to 6.4 ± 1.4 mg dl − 1 , P = 0.017), whereas that in the Lower Group did not do so (4.6 ± 1.0 vs. 4.7 ± 0.9 mg dl − 1 , P = 0.641). UA, uric acid.
were observed. This might be because of the small sample size of this study. Nevertheless, the present study showed trends that were essentially similar to the results of the I-Mets study. A study with long-term observation and a larger sample size might show significant changes in these parameters, given that lipid metabolism, inflammation and oxidative stress are related to each other.
In the present study, fasting blood glucose, HbA1c, NT-proBNP and eGFR levels did not change significantly. However, several previous reports have demonstrated that reductions in serum UA level and oxidative stress help improve glucose metabolism, heart failure and renal function; therefore, similar effects of irbesartan might be demonstrable if patients are stratified according to baseline UA level.
Regarding cardiovascular end points, a subanalysis of the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study showed that the superior effects of losartan can be partly explained by its effect on serum UA level. 39 However, coronary artery disease and heart failure guidelines do not include recommendations for the control of serum UA level, 40 because UA has variable associations with different cardiovascular disease states. 41 As serum UA level at baseline and gender both influence the effects of UA-lowering therapy, 41 when evaluating treatment efficacy, it may be important to stratify patients using several parameters. As the UA-lowering effect of irbesartan in the present study was only observed in patients whose baseline UA level exceeded the median value, the threshold value and mechanism of this apparent effect warrant further study. In addition, a limitation of this study is that it was not a randomized controlled trial. Therefore, prospective, randomized, controlled trials evaluating hard end points are needed to confirm that lowering UA level improves the long-term outcomes of cardiovascular diseases. Finally, future basic research should elucidate the interactions of the roles of UA, oxidative stress and inflammation in vivo.
CONCLUSION
In high-risk hypertensive patients, irbesartan may exhibit beneficial effects on hyperuricemia in addition to its effects on oxidative stress.
